Propanc Biopharma, Inc. · NASDAQ:PPCB
Propanc Biopharma — Investor Presentation (April 2024)
26 slides from Propanc Biopharma's investor presentation, Apr 10, 2024
Slide 1: Propanc Biopharma, Inc.
@® Propanc Biopharma, Inc. Developing a Novel Approach to Treat Metastatic Solid Tumors James Nathanielsz, Chief Executive Officer Jnathanielsz@propanc.com | wwmpropanc.com
Slide 2: Forward-Looking Statement
Forward-Looking Statement The information in this presentation is provided to you by Propane Biopharma, Inc. (the “Company") solely for informational purposes and is not an offer to buy or sell, or a solicitation of an offer to buy or sell, any security of instrument of the Company, or to participat
Slide 3: Summary
Summary EM overview | 2 Ver Asset: PRP OEM rec-pre Program BEA corporate Overview
Slide 4: Investment Highlights
Investment Highlights Generated compassionate use (CU) data across 46 terminal patients where 41% exceeded life expectancy without any serious adverse events Initially targeting Pancreatic and Ovarian cancers with combined TAM of $14.3B and long-term strategy of targeting metastatic solid tumors (~$
Slide 5: Management
Management James Nathanielsz Chief Executive & Chief Financial Officer Director & CEO since Oct. 2007 25 yrs. experience in R&D, ‘Manufacturing & Distribution, including 15 yrs. in oncology pharmaceutical drug development. Bachelor of Applied Science Giochemistry/ Applied Chemistry) & Master of Entr
Slide 6: Focused Pipeline Candidates
Focused Pipeline Candidates Indications DrugCandidate _ Discovery Phase 1 Phase 2 Status Pancreatic | Initiate Phase Ib in | See) | 2H 2024; Interim op RP + results expected in 2 ‘Ovarian Cancer | Chemotrypsinogen) | POP1 Entering preclinical development 2H 2024 Synthetic (Trypsinogen + | Chemotryps
Slide 7: Large Addressable Market with Unmet Need
Large Addressable Market with Unmet Need Global Cancer Treatment Market Size $251.18B 91% of cancer cases are solid tumors ~$111B Global metastatic cancer market by 2027 CAGR 9.2% ~$14.3B 1.8M Global Pancreatic and Ovarian New cases of cancer markets by 2027 solid tumors in the US. ~$4.2B ~$10.1B Gl
Slide 8: Slide 8
Slide 9: Technology Based on Pancreatic Enzyme Therapy
Technology Based on Pancreatic Enzyme Therapy Propanc Biopharma's PRP (Proenzyme Therapy) offers a groundbreaking approach to treating metastatic solid tumors, addressing critical challenges in the cancer treatment market. V Selective Targeting of Tumor Cell Targeting Cancer Stem Cells VW Proenzyme
Slide 10: PRP: Proenzyme Formulation Derived from Pancreas
PRP: Proenzyme Formulation Derived from Pancreas A780 - Ovarian Mixture of 2 sis proenzymes from 020.08 bovine pancreas _— "© Chymatyesnogen FF tttst~wSSSSS oe (© Ponca pare See ee end amylose a A — tu ‘ i008 HCT-15- Colorectal vere cele o Strong responses include ovarian and colorectal cancers ‘man
Slide 11: PRP: Novel Mechanism of Action
PRP: Novel Mechanism of Action LY Targets cscs Inhibits Cancer Stem Cells (CSC) Related Genes Primary tumour sends 2) Prevents Metastasis Differentiates Malignant Cells to Become Safer messengers to prepare the pre-metastatic niche. PRP acts blocking those messengers {EMT process G2% Tere f | Hope p
Slide 12: PRP: Suppresses EMT Process and Metastasis
PRP: Suppresses EMT Process and Metastasis Soret Up-Regulation Promotes RAC1 Preventing Hyper-acti of TGF- B Pathway [EMT process _| GFE | Hippo patrway |e \|2 | notch | | eaahern Inhibits the EMT s the EMT Process That Leads to Metastatic Cancer ® Propanc
Slide 13: PRP: Alters EMT Signaling Pathways
PRP: Alters EMT Signaling Pathways Cancer stem cells die naturally B 16 * by reprogramming the cancer 4a he BxPC3 stem cell to reduce malignancy 12 and invasiveness 1 08 mcTR 5 oe E 2 Go $04 Ey z & 02 PRP promotes the expression of i] ° / E-cadherin and decreases 3 ECAD VIMENTINE expression of N-cad
Slide 14: Compassionate Use (CU) Study Data
Compassionate Use (CU) Study Data wy wy Mean survival of 9 months; significantly 46 terminal patients No severe, or even More than 40% of administered serious adverse patients significantly ppository events observed from exceeded life formulation treatment expectancy higher than mean life xpectancy
Slide 15: Improving on CU Results
Improving on CU Results Formulation Optimized Compassionate use study was meant as a proof of concept; only tested a 1:1 ratio of proenzymes _ Administration Improved PRP will be an IV administration, making it a far simpler and direct delivery of drug | i Systemic Exposure Because of synergistic ra
Slide 16: CU Data Highlights Market Value
CU Data Highlights Market Value Compassionate use study highlighted 41% of patients exceeded life expectancy with the average survival of patients almost doubling from 5.6 months at original prognosis to 9 months. Additionally, there was a superior safety profile with no serious adverse events obser
Slide 17: PRP Phase 1b Study Design
PRP Phase 1b Study Design Design Open-label, multicenter, non- comparative, safety and pharmacokinetic study of PRP administered at increasing dose levels, once weekly as intravenous injection of a 28-day (4-week) cycle The study consists of an accelerated escalation phase and a subsequent standard
Slide 18: POP1 / Rec-PRP
POP1 / Rec-PRP Human Recombinant Version of PRP
Slide 19: Rec-PRP Program: Synthetic Enzymes
Rec-PRP Program: Synthetic Enzymes Our research has produced synthetic versions of the two proenzymes using a novel expression system to achieve high titers of recombinant trypsinogen and chymotrypsinogen Anti-cancer effects to be tested against naturally derived proenzymes of bovine origin Goal to
Slide 20: Rec-PRP Demonstrated Preclinical Results
Rec-PRP Demonstrated Preclinical Results Novel therapeutic formulation based on the combination of human recombinant trypsinogen & chymotrypsinogen produced synthetically 50 40 | a Demonstrated the reduced viability of CSCs and xz % decreased the expression of CSC markers 8 ae R20 | 2 Showed a simil
Slide 21: Corporate Overview
Corporate Overview
Slide 22: Therapeutic Landscape
Therapeutic Landscape Targeted Therapies PRP Therapy Chemotherapeutics _(e.g., Multi-targeted Kinase inhibitors) Monoclonal Antibodies Immunotherapy Pain, diarrhoea, oe Nosevereorseriousside | 2Mstipation, mouth sores, atigue, cash, hand-foot Skin and gastrointestinal Skin and gastrointestinal Sever
Slide 23: Early Data Shows Promise Among Alternatives
Early Data Shows Promise Among Alternatives ELEVATION eee FibroGen Ticker ELEV FGEN Share Price $4.41 $1.71 Market Cap. $187M $169M Phase of Dev. Ph.1 Study Ongoing Ph.3 Ongoing Ph. 1/2 Ongoing Overview Gein OAeG ABE eAED MOA is fully human antibody Uncertainty around PRMTS class / ieee ~~ against c
Slide 24: Clinical Development Timelines
Clinical Development Timelines Months ® Propanc
Slide 25: What's Next?
What's Next? ft Significant Value Already Short Timelines and Limited Capital Unlocked Required for Next Milestones Completed Tasks Planned Activities Scientific advice meetings with MHRA (UK) nee ‘Orphan Drug Designation Status received from FDA for Development of bio-analytical assays to quantify
Slide 26: Investment Highlights
Investment Highlights Generated compassionate use (CU) data across 46 terminal patients where 41% exceeded life expectancy without any serious adverse events Initially targeting Pancreatic and Ovarian cancers with combined TAM of $14.3B and long-term strategy of targeting metastatic solid tumors (~$
Propanc Biopharma — Investor Presentation (April 2024) on 6ix